MADDEN SECURITIES Corp Sells 23,426 Shares of Bristol Myers Squibb Company $BMY

MADDEN SECURITIES Corp lessened its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 48.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 24,724 shares of the biopharmaceutical company’s stock after selling 23,426 shares during the quarter. MADDEN SECURITIES Corp’s holdings in Bristol Myers Squibb were worth $1,115,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Bristol Myers Squibb by 1.8% during the second quarter. Vanguard Group Inc. now owns 194,925,206 shares of the biopharmaceutical company’s stock valued at $9,023,088,000 after purchasing an additional 3,522,202 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Bristol Myers Squibb by 16.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after buying an additional 10,195,775 shares during the period. Geode Capital Management LLC lifted its position in shares of Bristol Myers Squibb by 1.6% during the 2nd quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company’s stock valued at $2,132,976,000 after buying an additional 723,459 shares in the last quarter. Norges Bank bought a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $1,554,154,000. Finally, Ameriprise Financial Inc. increased its holdings in Bristol Myers Squibb by 1.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock worth $1,508,099,000 after acquiring an additional 432,158 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: UBS upgraded BMY, citing improved fundamentals and/or valuation support from recent earnings and guidance — a boost for investor confidence and likely a contributor to buying interest. Bristol Myers Squibb (NYSE:BMY) Stock Rating Upgraded by UBS Group
• Positive Sentiment: Piper Sandler reiterated a buy rating for BMY, reinforcing sell‑side support and reducing downside risk from analyst sentiment. Piper Sandler Sticks to Their Buy Rating for Bristol-Myers Squibb (BMY)
• Positive Sentiment: BioNTech and Bristol Myers Squibb expanded a pancreatic cancer program with a new Phase II trial — clinical progress in a high‑need oncology indication improves long‑term upside potential if data are positive. BioNTech and Bristol-Myers Squibb Push Deeper Into Pancreatic Cancer With New Phase II Trial
• Positive Sentiment: BMY added a new immunotherapy combo in small‑cell lung cancer, broadening its oncology pipeline and potential label-expansion or combination opportunities. Pipeline depth tends to support premium multiples in pharma names. Bristol Myers Squibb Adds New Immunotherapy Combo Bet in Small Cell Lung Cancer
• Neutral Sentiment: Analyst/industry pieces (Argus, Yahoo valuation reviews, and a Zacks recap) note BMY’s recent share gains and evolving profitability story but raise valuation questions as shares have recovered — these provide context but no immediate directional trigger. Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves
• Neutral Sentiment: CNBC preview of the JPMorgan Healthcare Conference highlights that the event could be a catalyst (pipeline updates, commercialization and M&A talk) for BMY, but outcomes depend on what management and peers announce. Healthy Returns: What to expect from pharma at the JPM conference
• Neutral Sentiment: Headline pieces summarizing recent developments (Yahoo/TipRanks recaps) provide useful investor reading but are largely descriptive rather than delivering a single market-moving event. How Recent Developments Are Shaping The Bristol Myers Squibb (BMY) Investment Story

Bristol Myers Squibb Stock Up 0.0%

BMY opened at $55.92 on Friday. The company has a market capitalization of $113.84 billion, a PE ratio of 18.89, a price-to-earnings-growth ratio of 9.29 and a beta of 0.29. The firm has a 50-day simple moving average of $50.93 and a two-hundred day simple moving average of $47.80. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The firm had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.75 billion. During the same period in the previous year, the firm posted $1.80 earnings per share. The business’s revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.5%. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is currently 85.14%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 17th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Scotiabank reiterated a “sector perform” rating and issued a $60.00 price target (up previously from $53.00) on shares of Bristol Myers Squibb in a research note on Friday. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Finally, UBS Group upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their target price for the stock from $46.00 to $65.00 in a research report on Wednesday. Six analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and an average price target of $56.62.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.